I-Mab Reports Initial Positive Data from US Trial of CD47 Candidate

Shanghai's I-Mab, reported positive initial results from a US Phase I trial of its CD47 treatment for relapsed or refractory solid tumors and lymphoma. The candidate, lemzoparlimab, was designed to lessen the toxicity of CD47 drugs by avoiding binding to red blood cells. In the trial, lemzoparlimab was well tolerated without dose-limiting toxicity or anemia. Next, it will be tested in combination with other drugs. In September , I-Mab announced a nearly $2 billion global partnership with AbbVie for lemzoparlimab. More details.... Stock Symbols: (NSDQ: IMAB) (NYSE: ABBV) Share this with colleagues: // //